Cancer Geneticist, Alberto Bardelli, Ph.D., Joins TrovaGene, Inc.'s Scientific Advisory Board

SAN DIEGO, Sept. 17, 2014 /PRNewswire/ -- Trovagene, Inc., (NASDAQ: TROV) a developer of cell-free molecular diagnostics, announced today that Alberto Bardelli, Ph.D., has joined the Company’s Scientific Advisory Board. Dr. Bardelli was among the first to identify mutations in the kinase genes that are associated with colorectal cancer and other malignancies. Currently, he is at the Department of Oncology, Torino Medical School, Institute for Cancer Research in Candiolo, Italy.

“Alberto’s work in cancer genomics has had a profound impact on the diagnosis and treatment of cancer,” stated Mark Erlander, Ph.D., chief scientific officer of Trovagene. “His perspectives on personalizing oncology treatment will provide valuable insights as we continue to demonstrate the clinical utility of our precision cancer monitoring platform in order to support broad market adoption.”

“Genomic testing is becoming essential in cancer treatment, and physicians must be able to monitor a patient’s mutational status closely,” said Dr. Bardelli. “One of my objectives is to advise Trovagene as the Company continues to expand its precision cancer monitoring platform and integrate this novel technology in clinical practice.”

Dr. Bardelli is a pioneering scientist in the field of cancer genomics and the modelling of cancer using isogenic cell-lines. He developed a generation of isogenic cell-lines harboring subtle kinase mutations designed to accurately predict responses to appropriately targeted agents in humans. Based on this research, Dr. Bardelli co-founded Horizon Discovery Group, plc, one of the fastest growing biotechnology companies in Europe. In 2014, Dr. Bardelli was nominated by Thomson Reuters in the list of the world’s most influential scientific minds. He currently serves as associate professor at the Department of Oncology at the University of Torino as well as Director, Laboratory of Molecular Genetics at The Institute for Cancer Research and Treatment, IRCC (TO), Italy. Since 2004, Dr. Bardelli has directed a research group at the Department of Oncology at the University of Torino, focused on the identification of mutations in oncogenes that may represent valid therapeutic targets for human cancers and the development of targeted therapies. A cum laude graduate of the University of Torino with an undergraduate degree in biological sciences, Dr. Bardelli earned his Ph.D. in biochemistry and molecular biology from University College London. He served as a postdoctoral fellow at Johns Hopkins University; School of Medicine and the Howard Hughes Medical Institute from 1999 2004, and received the prestigious Alfred Blalock Research Award in 2004.

About Trovagene, Inc.

Headquartered in San Diego, California, Trovagene is leveraging its proprietary technology for the detection and monitoring of cell-free DNA in urine. The company’s technology detects and quantitates oncogene mutations in cancer patients for improved disease management. Trovagene’s precision cancer monitoring platform is designed to provide important clinical information beyond the current standard of care, and is protected by significant intellectual property including multiple issued patents and pending patent applications globally.

Certain statements in this press release are forward-looking within the meaning of the Private Securities Litigation Reform Act of 1995. These statements may be identified by the use of forward-looking words such as “anticipate,” “believe,” “forecast,” “estimated” and “intend,” among others. These forward-looking statements are based on Trovagene’s current expectations and actual results could differ materially. There are a number of factors that could cause actual events to differ materially from those indicated by such forward-looking statements. These factors include, but are not limited to, substantial competition; our ability to continue as a going concern; our need for additional financing; uncertainties of patent protection and litigation; clinical trials involve a lengthy and expensive process with an uncertain outcome, and results of earlier studies and trials may not be predictive of future trial results; uncertainties of government or fourth party payer reimbursement; limited sales and marketing efforts and dependence upon fourth parties; and risks related to failure to obtain FDA clearances or approvals and noncompliance with FDA regulations. As with any medical diagnostic tests under development, there are significant risks in the development, regulatory approval and commercialization of new products. There are no guarantees that future clinical trials discussed in this press release will be completed or successful or that any product will receive regulatory approval for any indication or prove to be commercially successful. Trovagene does not undertake an obligation to update or revise any forward-looking statement. Investors should read the risk factors set forth in Trovagene’s Form 10-K for the year ended December 31, 2013 and other periodic reports filed with the Securities and Exchange Commission.

Contact

Logo - http://photos.prnewswire.com/prnh/20120620/LA28014LOGO

SOURCE Trovagene, Inc.